EUVIMEDEUVIMED entdecken
Crossref

Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer

Yiyao Wang, Hanqi Lei, Binyuan Yan, Shiqiang Zhang, Bin Xu, Minzhao Lin, Xintao Shuai, Jinsheng Huang, Jun Pang

Acta Biomaterialia · 2023-09 · 168 · 593-605

DOI: 10.1016/j.actbio.2023.07.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2023-09. Verfasst von Yiyao Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 51…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Prostatic Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Sun Yat-sen University, Medical Science and Technology Foundation of Guangdong Province, Science, Technology and Innovation Commission of Shenzhen Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade (ICB) antibody such as anti-PD-L1 (aPD-L1) activates cytotoxic T cells (CTLs) to combat cancer, but they showed poor efficacy in prostate cancer (PCa). Lysosome-dependent autophagy is utilized by cancer cells to degrade their MHC-I and to lower their vulnerability to TNF-α and CTLs. Lysosomal pH-sensitive polymeric nanoparticle as a drug delivery carrier may also be a novel autophagy inhibitor to boost immunotherapy, but such an important effect has not been investigated. Herein, we developed a unique tumor acidity-activatable macromolecular nanodrug (called P-PDL1-CP) with the poly(2-diisopropylaminoethyl methacrylate) (PDPA) core and the conjugations of both aPD-L1 and long-chain polyethylene glycol (PEG) coating. The PDPA core was demonstrated to disturb lysosome to block the autophagic flux, thus elevating the cancer cell's MHC-I expression and vulnerability to the TNF-α and CTLs. Long-chain PEG facilitated a good tumor accumulation of P-PDL1-CP nanodrug. Furthermore, P-PDL1-CP nanodrug inhibited tumor autophagy, which synergized with aPD-L1 to promote the tumor-infiltrating CTLs and DCs maturation, to elevate intratumoral TNF-α and IFN-γ levels, and to elicit an anti-tumor immune memory effect in mice for PCa growth inhibition with low side effects. This study verified the synergistic anti-PCa treatment between autophagy inhibition and PD-L1 blockade and meantime broadened the application of pH-sensitive macromolecular nanodrug. STATEMENT OF SIGNIFICANCE: A macromolecular nanodrug, comprising the PDPA core and the surface conjugation of both aPD-L1 antibodies and long-chain PEG coating via a tumor acidity-labile α-carboxy-dimethylmaleic anhydride amine bond, was developed. Tumoral acidity triggered the release of aPD-L1 for immunotherapy. Meantime, the charge switch of the remanent nanodrug enhanced the cancer cell uptake of PDPA, which disturbed the lysosomes to inhibit autophagy. This advanced nanodrug promoted the tumor-infiltrating CTLs and DCs maturation, elevated the intratumoral TNF-α and IFN-γ levels, and elicited the robust anti-tumor immune memory effect. This study demonstrated that the pH-sensitive PDPA macromolecule could serve as a carrier for the aPD-L1 delivery and as an efficient autophagy inhibitor to boost the immunotherapy of prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsProstatic NeoplasmsHumansMaleAnimalsMiceTumor Necrosis Factor-alphaT-Lymphocytes, CytotoxicImmunotherapyCell Line, TumorAutophagyTumor Microenvironment

Stichwörter der Autor:innen

Immune checkpoint blockadeImmune escapeMacromolecule autophagy inhibitorProstate cancerpH sensitivity

Substanzen

Immune Checkpoint InhibitorsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, PR China.
  • Nanomedicine Research Center, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, PR China.
  • Nanomedicine Research Center, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, PR China. Electronic address: shuaixt@mail.sysu.edu.cn.
  • Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, PR China. Electronic address: huangjsh55@mail.sysu.edu.cn.
  • Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, PR China. Electronic address: pangjun2@mail.sysu.edu.cn.

Förderung

  • Sun Yat-sen University
  • Medical Science and Technology Foundation of Guangdong Province
  • Science, Technology and Innovation Commission of Shenzhen Municipality
  • Sanming Project of Medicine in Shenzen Municipality
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • National Natural Science Foundation of China

Zitieren

APA

Wang, Y., Lei, H., Yan, B., Zhang, S., Xu, B., Lin, M., Shuai, X., Huang, J., & Pang, J. (2023). Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer. Acta Biomaterialia, 168, 593-605. https://doi.org/10.1016/j.actbio.2023.07.018

Vancouver

Wang Y, Lei H, Yan B, Zhang S, Xu B, Lin M, et al. Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer. Acta Biomaterialia. 2023;168:593-605. doi:10.1016/j.actbio.2023.07.018

BibTeX
@article{Wang2023,
  author = {Wang, Yiyao and Lei, Hanqi and Yan, Binyuan and Zhang, Shiqiang and Xu, Bin and Lin, Minzhao and Shuai, Xintao and Huang, Jinsheng and Pang, Jun},
  title = {Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer},
  journal = {Acta Biomaterialia},
  year = {2023},
  volume = {168},
  pages = {593--605},
  doi = {10.1016/j.actbio.2023.07.018}
}
Kostenlos starten →